ZyVersa Therapeutics, Inc.

NasdaqCM ZVSA

ZyVersa Therapeutics, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2024: USD -2.42 B

ZyVersa Therapeutics, Inc. Net Income is USD -2.42 B for the Trailing 12 Months (TTM) ending September 30, 2024, a -2,596.64% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

ZyVersa Therapeutics, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -89.75 M, a -703.74% change year over year.
ZyVersa Therapeutics, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -11.17 M.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

NasdaqCM: ZVSA

ZyVersa Therapeutics, Inc.

CEO	Mr. Stephen C. Glover
IPO Date	Feb. 11, 2022
Location	United States
Headquarters	2200 N. Commerce Parkway
Employees	7
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

Key trends

Past 5 years